A Peptide Inhibitor of c-Jun N-Terminal Kinase for the Treatment of Endotoxin-Induced Uveitis
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the effect of XG-102 (formerly D-JNKI1), a TAT-coupled dextrogyre peptide that selectively inhibits the c-Jun N-terminal kinase, in the treatment of endotoxin-induced uveitis (EIU). METHODS: EIU was induced in Lewis rats by LPS injection. XG-102 was administered at the time of LPS challenge. The ocular biodistribution of XG-102 was evaluated using immunodetection at 24 hours after either 20 microg/kg IV (IV) or 0.2 microg/injection intravitreous (IVT) administrations in healthy or uveitic eyes. The effect of XG-102 on EIU was evaluated using clinical scoring, infiltration cell quantification, inducible nitric oxide synthase (iNOS) expression and immunohistochemistry, and cytokines and chemokines kinetics at 6, 24, and 48 hours using multiplex analysis on ocular media. Control EIU eyes received vehicle injection IV or IVT. The effect of XG-102 on c-Jun phosphorylation in EIU was evaluated by Western blot in eye tissues. RESULTS: After IVT injection, XG-102 was internalized in epithelial cells from iris/ciliary body and retina and in glial and microglial cells in both healthy and uveitic eyes. After IV injection, XG-102 was concentrated primarily in inflammatory cells of uveitic eyes. Using both routes of administration, XG-102 significantly inhibited clinical signs of EIU, intraocular cell infiltration, and iNOS expression together with reduced phosphorylation of c-Jun. The anti-inflammatory effect of XG-102 was mediated by iNOS, IFN-gamma, IL-2, and IL-13. CONCLUSIONS: This is the first evidence that interfering with the JNK pathway can reduce intraocular inflammation. Local administration of XG-102, a clinically evaluated peptide, may have potential for treating uveitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interfering with the p38 pathway by the use of the specific inhibitor XG-102 has been shown to reduce intraocular inflammation [ 187 ] in a dose-dependent manner [ 188 ] in a rat LPS-induced uveitis model”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [187]
Citations
Cites
Multiplexed particle-based flow cytometric assays
Vignali, D. A. A. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00238-6 · Cited by 913
A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
Borsello, T., Clarke, P. G. H., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., & Bonny, C. (2003) · Nature Medicine · doi:10.1038/nm911 · Cited by 658
Targeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
Cell-Permeable Peptide Inhibitors of JNK
Bonny, C., Oberson, A., Negri, S., Sauser, C., & Schorderet, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.1.77 · Cited by 571
Swantek, J. L., Cobb, M. H., & Geppert, T. D. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6274 · Cited by 491
Jun N-Terminal Kinase in Rheumatoid Arthritis
Han, Z., Boyle, D. L., Aupperle, K. R., Bennett, B., Manning, A. M., & Firestein, G. S. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35079-7 · Cited by 156
Wang, J., Ruel, J., Ladrech, S., Bonny, C., Water, T. R. V. D., & Puel, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028936 · Cited by 153
Goureau, O., Bellot, J., Thillaye, B., Courtois, Y., & de Kozak, Y. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6518 · Cited by 140
Hirt, L., Badaut, J., Thevenet, J., Granziera, C., Regli, L., Maurer, F., Bonny, C., & Bogousslavsky, J. (2004) · Stroke · doi:10.1161/01.str.0000131480.03994.b1 · Cited by 133
Eshraghi, A. A., Wang, J., Adil, E. A., He, J., Zine, A., Bublik, M., Bonny, C., Puel, J., Bałkany, T. J., & Water, T. R. V. D. (2006) · Hearing Research · doi:10.1016/j.heares.2006.09.008 · Cited by 120
The JNK Are Important for Development and Survival of Macrophages
Himes, S. R., Sester, D. P., Ravasi, T., Cronau, S. L., Sasmono, T., & Hume, D. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2219 · Cited by 117
Suckfuell, >., Canis, M., Strieth, S., Scherer, H., & Haisch, A. (2007) · Acta Oto-Laryngologica · doi:10.1080/00016480601110212 · Cited by 105
Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis rats.
Jacquemin, E., de Kozak, Y., Thillaye-Goldenberg, B., Courtois, Y., & Goureau, O. (1996) · PubMed · Cited by 103
Ooi, K. G.-J., Galatowicz, G., Towler, H. M. A., Lightman, S. L., & Calder, V. L. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0790 · Cited by 94
Clancy, R. M., Rediske, J. J., Koehne, C. F., Stoyanovsky, D. A., Amin, A., Attur, M. G., Iyama, K.-I., & Abramson, S. B. (2001) · Osteoarthritis and Cartilage · doi:10.1053/joca.2000.0388 · Cited by 91
Iontophoresis of Dexamethasone in the Treatment of Endotoxin-Induced-Uveitis in Rats
BEHAR-COHEN, F. F., PAREL, J.-M., POULIQUEN, Y., THILLAYE-GOLDENBERG, B., GOUREAU, O., HEYDOLPH, S., COURTOIS, Y., & DE KOZAK, Y. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0364 · Cited by 87
Arbour, N., Naniche, D., Homann, D., Davis, R. J., Flavell, R. A., & Oldstone, M. B. A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011481 · Cited by 82
C-Jun N-Terminal kinase mediates disassembly of apical junctions in model intestinal epithelia
Naydenov, N. G., Hopkins, A. M., & Ivanov, A. I. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8928 · Cited by 68
c-Jun N-terminal kinase-dependent mechanisms in respiratory disease
Bennett, B. L. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00012106 · Cited by 63
Wiegler, K., Bonny, C., Coquoz, D., & Hirt, L. (2008) · Cerebrovascular Diseases · doi:10.1159/000151639 · Cited by 53
Barry, C. E., Nolan, Y., Clarke, R. M., Lynch, A., & Lynch, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.03011.x · Cited by 52
Repici, M., Mare, L. D., Colombo, A. V., Ploia, C., Sclip, A., Bonny, C., NICOD, P. H., Salmona, M., & Borsello, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.049 · Cited by 46
Marie, O., Thillaye-Goldenberg, B., Naud, M., & de Kozak, Y. (1999) · PubMed · Cited by 38
Self-citation(2002) · PubMed · Cited by 33
The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats.
Lemaître, C., Thillaye-Goldenberg, B., Naud, M., & de Kozak, Y. (2001) · PubMed · Cited by 32
Self-citationde Kozak, Y., Omri, B., Smith, J. R., Naud, M., Thillaye-Goldenberg, B., & Crisanti, P. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060236 · Cited by 29
Self-citationKamata, K. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00057-4 · Cited by 18
Baatz, H., & Pleyer, U. (2001) · Inflammation Research · doi:10.1007/pl00000231 · Cited by 15
Lin, H.-Y., Shen, S., Lin, C., Wu, M., & Chen, Y. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.01.004 · Cited by 14
Systemic Interferon-γ Suppresses the Development of Endotoxin-Induced Uveitis in Mice
Fukushima, A., Ozaki, A., Ishida, W., Fukata, K., & Ueno, H. (2005) · Current Eye Research · doi:10.1080/02713680490522461 · Cited by 6
Cited by
Cell-Penetrating Peptides: From Basic Research to Clinics
Guidotti, G., Brambilla, L., & Rossi, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.01.003 · Cited by 1,147
“In the context of pain and inflammation, Xigen SA moved into clinical development XG-102 (previously known as D-JNKI-1), a CPP inhibitor of JNK that was already shown to have potential for the treatment of intraocular inflammation in rat models of uveitis [33,111].”
BackgroundCell penetrating peptides: the potent multi-cargo intracellular carriers
Kardani, K., Milani, A., H. Shabani, S., & Bolhassani, A. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1676720 · Cited by 199
Role of the JNK Pathway in Human Diseases
Sabapathy, K. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00013-4 · Cited by 167
Girol, A. P., Mimura, K. K. O., Drewes, C. C., Bolonheis, S. M., Solito, E., Farsky, S. H. P., Gil, C. D., & Oliani, S. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202030 · Cited by 136
“Our in vivo analyses found that the inflammatory stimulus induced by LPS caused the release of chemical mediators (TNF-a, IL-1b, IL-6, and NO), increased expression of the proinflammatory enzyme COX-2, breakdown of the blood–ocular barrier, and intense influx of leukocytes in EIU 24h rats (9, 14, 21).”
BackgroundInhibitors of c-Jun N-Terminal Kinases: An Update
Koch, P., Gehringer, M., & Laufer, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501212r · Cited by 112
Metadata
- Authors
- Touchard, E., Omri, S., Naud, M.-C., Berdugo, M., Deloche, C., Abadie, C., Jonet, L., Jeanny, J.-C., Crisanti, P., de Kozak, Y., Combette, J.-M., & Behar-Cohen, F.
- Affiliations
- Inserm (FR)
- RibOvax Biotechnologies S.A., Geneva, Switzerland; and
- From the INSERM, U872 Physiopathology of Ocular Diseases/Therapeutic Innovations, Paris, France; 2Centre de Recherche des Cordeliers, Université Pierre et Marie Curie—Paris6, UMR S 872, Paris, France; 3Université Paris Descartes, UMR S 872, Paris, France;
- Corresponding author
- Touchard, Elodie
- Omri, Samy
- Naud, Marie-Christine
- Berdugo, Marianne
- Deloche, Catherine
- Abadie, Claire
- Jonet, Laurent
- Jeanny, Jean-Claude
- Crisanti, Patricia
- Combette, Jean-Marc
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-09-01
- Volume
- 51
- Issue
- 9
- Pages
- 4683
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2069483338
- Cited by
- 43
- References
- 30
- Citations by year
- 2023: 3 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 3 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 4
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- endotoxin-induced uveitis, intravitreal administration, inducible nitric oxide synthase, c-Jun phosphorylation, intraocular inflammation, cytokines and chemokines, interferon-gamma, interleukin-2, IL-13, lipopolysaccharide, uveitis treatment
- MeSH terms
- Animals, Disease Models, Animal, Drug Combinations, Female, Injections, Intravenous, Lipopolysaccharides, Oils, Peptides, Phenols, Rats, Inbred Lew, Tissue Distribution, Uveitis, Vitreous Body, Signal Transduction, Down-Regulation, Cytokines, Chemokines, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating), JNK Mitogen-Activated Protein Kinases, Rats, Nitric Oxide Synthase Type II, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.